TH2 cell compensatory effect following benralizumab treatment for eosinophilic gastritis
-
Published:2024-07
Issue:
Volume:
Page:
-
ISSN:0091-6749
-
Container-title:Journal of Allergy and Clinical Immunology
-
language:en
-
Short-container-title:Journal of Allergy and Clinical Immunology
Author:
Ben-Baruch Morgenstern Netali,
Rochman Yrina,
Caldwell Julie M.,
Collins Margaret H.,
Mukkada Vincent A.,
Putnam Philip E.,
Bolton Scott M.,
Kliewer Kara L.,
Rothenberg Marc E.ORCID
Reference22 articles.
1. Eosinophilic gastrointestinal disorders (EGID);Rothenberg;J Allergy Clin Immunol,2004
2. Local type 2 immunity in eosinophilic gastritis;Ben-Baruch Morgenstern;J Allergy Clin Immunol,2023
3. Pathophysiology of eosinophilic esophagitis;O'Shea;Gastroenterology,2018
4. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study;Castro;Am J Respir Crit Care Med,2011
5. Benralizumab for eosinophilic gastritis: a single-site, randomised, double-blind, placebo-controlled, phase 2 trial;Kliewer;Lancet Gastroenterol Hepatol,2023